CompletedPhase 2ACTRN12605000756628
Continued use of Atorvostatin in sepsis
A phase II randomised controlled trial in patients on statin therapy who develop sepsis to evaluate the effect of continued atorvastatin use on the incidence of severe sepsis
Sponsor
Dr Peter Kruger, Intensive Care Specialist, Princess Alexandra Hospital, Brisbane
Enrollment
200 participants
Start Date
May 8, 2006
Study Type
Interventional
Conditions
Summary
study completed and the results are now published in the American journal of Respiratory and critical care medicine
Eligibility
Sex: Both males and femalesMin Age: 18 Yearss
Inclusion Criteria1
- All patients with sepsis syndrome who are on statin therapy at the time of admisison to hospital are eligable for inclusion.
Exclusion Criteria1
- Pregnancy, acute liver failure or chronic liver disease ( more than Childs B), patients who are moribund and not expected to survive 24 hrs, patients with rhabdomyolysis or myopathy of any cause. Patients in whom any enteral intake will clearly not be possible within 72 hours.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Atorvostatin as continuation of statin therapy for a 28 day study period ( or until discharge form hospital)
Atorvostatin as continuation of statin therapy for a 28 day study period ( or until discharge form hospital)
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000756628